Expertise in
6
conditions

Yulong L. He

No.58 Zhongshaner Road, 
Guangzhou, CN 
Expertise in
6
conditions
No.58 Zhongshaner Road, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Yulong He practices in Guangzhou, China. He is highly rated in 6 conditions, according to our data. Their top areas of expertise are Stomach Cancer, Gastrointestinal Stromal Tumor, Colorectal Cancer, Gastrectomy, and Tissue Biopsy.

Their clinical research consists of co-authoring 399 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Locations

No.58 Zhongshaner Road, Guangzhou, 510080, China
Other Locations
China P.R, Shanghai, China
No. 628 Zhenyuan Road, Shenzhen, 518107, China
58 Zhongshan 2nd Road, Guangzhou, 510080, China
College Of Life Sciences & Institute For Conservation And Utilization Of Agro Bioresources In Dabie Mountains, Pingqiao, China
628 Zhenyuan Road, Shenzhen, 518000, China
100 Kexue Avenue, Zhengzhou, 450001, China
58 Zhongshan 2 Road, Guangzhou, 510080, China
No. 19A Yuquan Road, Yuquan, 100049, China
Sun Yat Sen University 58 Zhongshan 2nd Road, Guangzhou, 510080, China
Zhongshan Second Road, Guangzhou, 510080, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma
A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma
Enrollment Status: Unknown
Publish Date: April 25, 2017
Intervention Type: Drug
Study Drug: Anlotinib
Study Phase: Phase 2/Phase 3

399 Total Publications

Discovery of Potent and Selective FABP4/5 Inhibitors with an Isoquinolone Scaffold as Potential Therapeutics for Inflammation-Related Diseases.
Discovery of Potent and Selective FABP4/5 Inhibitors with an Isoquinolone Scaffold as Potential Therapeutics for Inflammation-Related Diseases.
Journal: Journal of medicinal chemistry
Published: September 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find He's expertise for a condition
ConditionClose
    View All 45 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile